Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 345.51% | -71.56% | 110.35% | 832.09% | -83.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 345.51% | -71.56% | 110.35% | 832.09% | -83.87% |
| Cost of Revenue | 66.18% | 54.27% | 31.06% | 51.18% | 18.15% |
| Gross Profit | -64.80% | -74.04% | -27.42% | -43.12% | -21.97% |
| SG&A Expenses | 18.86% | 16.20% | 22.30% | 26.41% | 37.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.61% | 45.71% | 29.38% | 45.83% | 21.91% |
| Operating Income | -54.50% | -59.50% | -26.40% | -39.49% | -25.06% |
| Income Before Tax | -63.97% | -8.74% | -10.09% | -17.51% | -11.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.97% | -8.74% | -10.09% | -17.51% | -11.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.97% | -8.74% | -10.09% | -17.51% | -11.74% |
| EBIT | -54.50% | -59.50% | -26.40% | -39.49% | -25.06% |
| EBITDA | -55.33% | -60.64% | -26.85% | -40.28% | -25.48% |
| EPS Basic | -45.42% | 14.74% | 21.51% | 15.89% | 10.39% |
| Normalized Basic EPS | -45.42% | -19.86% | 21.52% | 15.89% | 10.39% |
| EPS Diluted | -45.42% | 14.74% | 21.51% | 16.48% | 10.39% |
| Normalized Diluted EPS | -45.42% | -19.86% | 21.52% | 15.89% | 10.39% |
| Average Basic Shares Outstanding | 12.76% | 27.53% | 40.27% | 39.71% | 24.69% |
| Average Diluted Shares Outstanding | 12.76% | 27.53% | 40.27% | 39.71% | 24.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |